Does efgartigimod help improve symptoms for myasthenia gravis patients?
Efgartigimod is a medication that blocks the neonatal Fc receptor (FcRn), reducing levels of harmful antibodies that attack the neuromuscular junction in myasthenia gravis (MG). Multiple studies show that efgartigimod can improve muscle weakness, fatigue, and daily functioning in people with generalized MG, including those who have not responded well to other treatments. It is given as an intravenous or subcutaneous infusion, typically in cycles.
What the research says
A large meta-analysis of 29 studies involving 1,594 MG patients found that 83% achieved a clinically meaningful improvement (at least a 2-point drop on the MG-ADL scale, which measures daily living activities), and 36% reached minimal symptom expression (MG-ADL score of 0 or 1) 1. The same analysis showed significant reductions in the Quantitative Myasthenia Gravis (QMG) score, a measure of muscle strength, by an average of 3.6 points 1. A separate systematic review of randomized trials confirmed that FcRn blockers like efgartigimod more than doubled the odds of achieving meaningful improvements in MG-ADL and QMG scores compared to placebo 6. Real-world data from 22 patients treated at multiple centers reported that 86.3% improved by at least 2 MG-ADL points after the first treatment cycle, with median scores dropping from 6.5 to 2.5 9. The effect typically lasted 4 to 12 weeks, and patients often required repeated cycles 9. A phase 3 trial also showed that subcutaneous efgartigimod is as effective as the intravenous form, with improvements seen as early as one week after the first dose 8. Importantly, efgartigimod appears to work in both AChR-antibody-positive and -negative MG patients, with no significant difference in response between these subtypes 1. The medication is generally well-tolerated; common side effects are mild, though serious events like respiratory failure have been reported rarely 9.
What to ask your doctor
- Is efgartigimod a treatment option for my type of myasthenia gravis, given my antibody status and symptom severity?
- How is efgartigimod administered (IV or subcutaneous), and what does a typical treatment cycle look like?
- What are the most common side effects, and how are they managed?
- How long does it usually take to see improvement, and how often would I need repeat cycles?
- Can efgartigimod be used alongside my current medications, such as prednisone or pyridostigmine?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.